Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Mallinckrodt emerges from chapter 11
We advised an ad hoc group of first-lien noteholders
Bristol Myers Squibb $4.5 billion notes offering
The investment-grade offering comprised four tranches
Alector $125 million at-the-market offering
The common stock is listed on the Nasdaq Global Select Market
NeuroPace $50 million at-the-market offering
The stock is listed on the Nasdaq Global Market
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
GSK exclusive license agreement for HS-20089 with Hansoh Pharma
We advised GSK on the transaction
GSK collaboration extension and new data licensing agreement with 23andMe
We advised GSK on the transaction
IDEAYA Biosciences $143.8 million equity offering
The common stock is listed on the Nasdaq Global Select Market
Aligos Therapeutics $92 million private placement
The PIPE included common stock and warrants
Roche $7.1 billion acquisition of Telavant and rights to RVT 3101 from Roivant
We are advising Roche on the acquisition